Smart Money Ratings For 20 Most Undervalued Stocks

Page 3 of 18

16. Avantor, Inc. (NYSE:AVTR)

Insider Transaction: 0.20%

Upside Potential: 33.50%

Forward P/E: 10.54

Avantor, Inc. (NYSE:AVTR), headquartered in Pennsylvania, is a provider of mission-critical products and services to the biopharma, healthcare, education, and advanced technology industries with an operational reach across the globe. The company’s portfolio is comprised of laboratory chemicals, equipment, and bioprocessing solutions. Against market players like Thermo Fisher and Merck KGaA, Avantor, Inc. (NYSE:AVTR) generates market share by integrating supply chain services with proprietary product offerings. Its end-to-end procurement platforms and strategic global distribution network give the company a strong foothold amid growing demand for life sciences.

The company’s value narrowly avoids the bottom by trading at a mere 1.00% higher than its 52-week low. Despite the challenging market conditions, though negative, the company’s earnings and margin during the first quarter of 2025 align with its plans. The demand in the key markets, such as the education and government sectors, has been weak, causing a decline in the company’s revenue. However, as part of the plan for 2025, Avantor, Inc. (NYSE:AVTR) intends to implement a delivery excellence initiative that could elevate supply chain efficiency as well as resilience. The AI-enabled e-commerce platform and other new products and distribution agreements are anticipated to support the company’s expansion into 2025.

With a low forward P/E ratio of 10.54, the company appears to be undervalued. Insider activity has been minimal for the past six months at 0.20%. With 39 hedge funds maintaining positions, institutional support remains better than internal confidence. Analysts anticipate a 33.50% upside, suggesting Avantor, Inc. (NYSE:AVTR) as a rebound candidate to be placed under watchful scrutiny.

Page 3 of 18